Search
Denosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigational[A263066] An Denosumab biosimilar, Jubbonti, was approved for Health Canada in February 2024.[L52083]. … [A263066] Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women.
Products: XGEVA® 120 MG/1.7 ML, XGEVA Solution for Injection 120 mg/vialMelatonin
go.drugbank.com/drugs/DB01065ApprovedInvestigationalNutraceuticalVet approvedReduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers.
Synonyms: 5-methoxy-N-acetyl tryptamine, 5-methoxy-N-acetyltryptamineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesAtosiban
go.drugbank.com/drugs/DB09059ApprovedInvestigationalAtobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985. … Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form.
Products: Atosiban EVER Pharma 75 mg/10 ml Konzentrat zur Herstellung einer Infusionslösung, TRACTOCILE 37.5 MG/ 5 ML CONCENTRADO PARA SOLUCION POR INFUSIONTenoxicam
go.drugbank.com/drugs/DB00469ApprovedInvestigationalTenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesProducts: TENOKTIL 20 MG KAPSÜL, 10 ADET, TILCOTIL 20 MG 10 SUPPAtezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigational[L7489] Atezolizumab was granted FDA approval on 18 October 2016.
Products: TECENTRIQ CONCENTRATE FOR SOLUTION FOR INFUSION 1200 MG/ 20 ML, TECENTRIQ 1200 MG / 20 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADETCalcium ascorbate
go.drugbank.com/drugs/DB14483ApprovedNutraceuticalMixtures: Ester-C 500 mg, Ester-C 500 mgProducts: Ester-C (1000 Mg), Extra C 500Digoxin
go.drugbank.com/drugs/DB00390ApprovedInvestigational[A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. … They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.[A178240]
International brands: Digocard-GProducts: DIGOXIN-ASSOS 0,250 MG TABLET, 50 ADET, DIGOXIN-ASSOS 0,5 MG /2 ML IV ENJEKSİYON İÇEREN AMPUL, 5 ADETDeferasirox
go.drugbank.com/drugs/DB01609ApprovedInvestigationalDeferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP1A2 InhibitorsProducts: EXJADE (500 MG), RASIROX® 500 MGMoxifloxacin
go.drugbank.com/drugs/DB00218ApprovedInvestigationalBayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Synonyms: 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acidMixtures: Ixoba MCaspofungin
go.drugbank.com/drugs/DB00520ApprovedInvestigationalCaspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc.
Synonyms: (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-transCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors